TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A MedPage Today roundup published Oct. 27, 2026, highlighted three studies on head shape and Alzheimer’s pathology, prenatal phosphatidylcholine and children’s outcomes, and platelet genetics that may affect aspirin’s relationship with dementia prevention. The findings are research signals, not proof of cause and effect or guidance to start supplements or aspirin.
A MedPage Today neurology roundup published Oct. 27 reported three findings relevant to Alzheimer’s disease and dementia: research examining whether head shape is linked to Alzheimer’s pathology, a randomized trial associating prenatal phosphatidylcholine supplements with some child outcomes through age 4, and an analysis suggesting platelet genetic scores may affect how aspirin relates to dementia prevention. The summaries describe early or limited evidence; they do not establish that head shape causes Alzheimer’s, that prenatal supplements raise IQ in all children, or that aspirin should be used to prevent dementia.
The roundup’s item on head shape, attributed to the journal Alzheimer’s & Dementia, asks whether head shape can influence Alzheimer’s disease pathology. The supplied report does not provide the study design, sample size, specific head-shape measures, or results, so it is not possible from this summary to say what association researchers found or whether head shape was linked to disease processes.
A randomized trial reported in the American Journal of Obstetrics and Gynecology found that children whose mothers received prenatal phosphatidylcholine supplements had fewer social-withdrawal problems and higher IQ test performance through age 4. The trial did not find a reduction in attention problems. The report does not give the size of the effects, the number of participants, or details about the supplement dose, limiting how fully the result can be evaluated here.
A separate analysis of data from the ASPREE trial, published in Alzheimer’s & Dementia, suggested that platelet-count polygenic scores may influence how aspirin might prevent dementia. The summary says certain subgroups of older adults may benefit, but does not specify which genetic profiles, the size of any effect, or whether aspirin reduced dementia outcomes overall. It presents a possible difference in response, not a general recommendation to take aspirin.
What the Findings Could Mean
Together, the reports touch on different points in brain health: possible biological factors associated with Alzheimer’s pathology, prenatal nutrition and children’s development, and whether inherited differences may modify a medicine’s relationship with dementia risk. The findings matter because they could inform future research into risk, development and treatment response.
For readers, the key distinction is between a research signal and a clinical conclusion. The prenatal trial reported selected outcomes through age 4, not a lasting effect across later childhood or proof that supplementation should be routine. The aspirin analysis suggests that effects may differ among groups, but the available summary does not establish who might benefit or whether the possible benefit outweighs bleeding risks. Neither finding supports changing medication or supplement use without individualized medical advice.
Products Worth Considering
Withings Body Scan Smart Scale with Segmental Body Composition and ECG, Black
Garmin Forerunner 55 GPS Running Smartwatch, Black
Oral-B iO Series 3 Rechargeable Electric Toothbrush for Adults, Black, with 2 Brush Heads and Travel Case
As an affiliate, we earn on qualifying purchases.
Three Questions From Neurology Research
The source is a short research roundup, not a report of one coordinated study. Its three items draw on different publications and methods, and the supplied material gives only brief descriptions. That means the head-shape question, randomized prenatal supplement trial, and ASPREE genetic analysis should be understood as separate developments rather than evidence for one shared explanation of dementia.
The roundup also covered other neurology topics, including an Alzheimer’s platform trial planned in the U.K. that will begin by testing repurposed medicines metformin and atomoxetine, and research on cognitive resilience. Those items provide wider context for the report’s focus on ongoing efforts to study dementia, but they do not resolve the three findings summarized here.
Key Evidence Still Missing
The supplied source does not include the underlying papers’ full methods, participant numbers, statistical results, or limitations. For the head-shape finding, the reported summary poses a research question but gives no result. For prenatal phosphatidylcholine, the duration of follow-up reported is through age 4; the summary does not say whether differences persist or how large they were. For aspirin, it does not identify the relevant platelet genetic-score groups or quantify a possible dementia-prevention effect.
It is also unclear from the roundup whether any findings have been replicated in independent populations. The reported associations and trial outcomes should not be treated as proof that head shape determines Alzheimer’s risk, that supplements reliably improve IQ, or that aspirin prevents dementia for a defined group.
Full Studies and Follow-Up Data
The next step for readers seeking a firmer assessment is the publication-level evidence: the full articles in Alzheimer’s & Dementia and the American Journal of Obstetrics and Gynecology, along with the ASPREE analysis. Those papers can clarify study populations, methods, effect sizes and limitations that are absent from the roundup.
Further follow-up will be needed to determine whether the prenatal trial’s child outcomes continue beyond age 4 and whether genetic differences meaningfully alter aspirin’s effects on dementia outcomes. Until those details and additional evidence are available, the reports are best read as research developments rather than changes to routine care.
Key Questions
Does the report show that head shape causes Alzheimer’s disease?
No. The roundup says researchers asked whether head shape can influence Alzheimer’s pathology, but the supplied summary provides no study results and does not establish a causal link.
What did the prenatal phosphatidylcholine trial report?
It reported fewer social-withdrawal problems and higher IQ test performance through age 4 among offspring, but no reduction in attention problems. The summary does not provide effect sizes or enough detail to support conclusions about all pregnancies.
Should older adults take aspirin to prevent dementia?
The report does not recommend that. It describes an ASPREE data analysis suggesting platelet genetic scores may affect aspirin’s relationship with dementia prevention; it does not identify who might benefit or establish an overall benefit. Aspirin use should be discussed with a clinician.
Are these three findings from one study?
No. They are separate research items from different publications and study approaches, collected in a MedPage Today neurology roundup.
Source: medpagetoday.com
